Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): November 23, 2005

 

 

ALEXION PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

  

000-27756

  

13-3648318

(State or other jurisdiction of

of incorporation or organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

 

352 Knotter Drive, Cheshire, Connecticut 06410

(Address of Principal Executive Offices) (Zip Code)

 

 

Registrant’s telephone number, including area code: (203) 272-2596

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

 

On November 23, 2005, Alexion Pharmaceuticals, Inc. issued a press release relating to results from its Phase III PRIMO-CABG2 clinical trial with pexelizumab. A copy of the press release is furnished as Exhibit 99.1 to this form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

 

(c) Exhibits

 

99.1     Press Release issued by Alexion Pharmaceuticals, Inc. on November 23, 2005.

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

        ALEXION PHARMACEUTICALS, INC.
Date: November 23, 2005       By:   /S/    THOMAS I. H. DUBIN        
               

Name: Thomas I. H. Dubin

Title: Senior Vice President and General Counsel

Index to Exhibits

 

Exhibit No.
  

Description

99.1   Press Release issued by Alexion Pharmaceuticals, Inc. on November 23, 2005.